Identifying and overcoming mechanisms of ALK tyrosine kinase inhibitor resistance in lung cancer cells bearing EML4-ALK gene fusions.

• Project/Area Number: 23790906
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Osaka University
• Principal Investigator: NAGATOMO Izumi 大阪大学, 大学院・医学系研究科, 特任助教(常勤) (10570583)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
• Keywords: 肺癌 / 薬剤耐性 / 分子標的治療薬 / EML4-ALK陽性肺癌

Research Abstract

EML4-ALK positive lung cancer cells (H2228 cell line) were cultured in medium containing an ALK kinase inhibitor (Crizotinib), and crizotinib-resistant cells were established. Second mutations within the ALK kinase-codingregion were not detected in those cells. Altered expression of four long non-coding RNAswere identified by real-time quantitative RT-PCR analyses in the resistant cells. Functional analyses of the alterations are in progress.